drugset / Trial / NCT06911203

A Study of BGM0504 in Participants With Obesity

NCT06911203

Phase 2 Recruiting 90 enrolled BrightGene Bio-Medical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.

Timeline

Start
2025-04-03
Primary completion
2026-01-11
Completion
2026-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BGM0504 Unknown Subcutaneous
Comparator Tirzepatide Peptide Subcutaneous

Indications